Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $31.37 and traded as low as $30.96. Maze Therapeutics shares last traded at $31.20, with a volume of 711,473 shares changing hands.
Analyst Ratings Changes
A number of research analysts recently weighed in on MAZE shares. Canaccord Genuity Group started coverage on Maze Therapeutics in a research note on Monday, October 19th. They issued a "buy" rating and a $75.00 price objective on the stock. Citigroup began coverage on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. They set a "buy" rating and a $50.00 price target for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Monday, September 21st. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Maze Therapeutics from $53.00 to $51.00 and set an "overweight" rating for the company in a research note on Wednesday, November 11th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $65.50.
Check Out Our Latest Analysis on MAZE
Maze Therapeutics Trading Down 5.1%
The company has a market capitalization of $1.71 billion, a P/E ratio of -11.77 and a beta of 2.04. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.14 and a current ratio of 14.14. The business has a fifty day moving average of $29.10 and a 200-day moving average of $31.37.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.01). Analysts anticipate that Maze Therapeutics, Inc. will post -2.76 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, CMO Harold Bernstein sold 16,141 shares of the firm's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.93, for a total transaction of $434,677.13. Following the sale, the chief marketing officer owned 16,141 shares of the company's stock, valued at $434,677.13. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $27.02, for a total transaction of $932,217.02. Following the completion of the transaction, the chief executive officer directly owned 15,558 shares of the company's stock, valued at $420,377.16. The trade was a 68.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 176,849 shares of company stock valued at $4,741,878. 5.30% of the stock is owned by insiders.
Institutional Investors Weigh In On Maze Therapeutics
Several hedge funds have recently modified their holdings of MAZE. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter valued at about $133,502,907. ARCH Venture Management LLC acquired a new position in Maze Therapeutics in the 2nd quarter valued at about $122,983,582. BlackRock Inc. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $104,525,000. Jupiter Topco LLC bought a new stake in Maze Therapeutics during the 2nd quarter worth approximately $101,764,000. Finally, Alphabet Inc. bought a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $41,435,000.
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company's Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.